Cerecor Inc (NASDAQ:CERC) Chairman Simon Pedder purchased 6,734 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was bought at an average price of $2.98 per share, with a total value of $20,067.32. Following the completion of the acquisition, the chairman now owns 262,734 shares in the company, valued at approximately $782,947.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of CERC traded down $0.17 during mid-day trading on Friday, reaching $2.93. 96,636 shares of the company’s stock traded hands, compared to its average volume of 73,573. The business’s 50-day moving average price is $3.63 and its 200-day moving average price is $4.94. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.71 and a current ratio of 0.74. Cerecor Inc has a 12 month low of $2.71 and a 12 month high of $7.65.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northern Trust Corp raised its holdings in shares of Cerecor by 47.9% during the fourth quarter. Northern Trust Corp now owns 20,079 shares of the company’s stock valued at $65,000 after buying an additional 6,500 shares during the last quarter. Charles Schwab Investment Management Inc. bought a new stake in shares of Cerecor during the second quarter valued at approximately $288,000. Geode Capital Management LLC raised its holdings in shares of Cerecor by 50.7% during the fourth quarter. Geode Capital Management LLC now owns 94,990 shares of the company’s stock valued at $306,000 after buying an additional 31,951 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Cerecor by 294.9% during the second quarter. Bank of New York Mellon Corp now owns 57,428 shares of the company’s stock valued at $312,000 after acquiring an additional 42,885 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in shares of Cerecor by 612.7% during the second quarter. JPMorgan Chase & Co. now owns 72,670 shares of the company’s stock valued at $355,000 after acquiring an additional 62,473 shares during the period. 57.92% of the stock is currently owned by institutional investors.
Cerecor Company Profile
Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.
Featured Article: Trading Strategy Methods and Types
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.